Abstract
We are entering a new era of biomedical research that is driven by the demand for more effective therapeutics to prevent and treat human disease. Organoids, cultured ex vivo, are the future of this new era of biomedical research and are poised to replace preclinical 2D cell models, and in some cases animal models of human disease. Therefore, the drug discovery and development pipeline is retooling high-throughput technologies to accommodate organoids as the model of choice. In particular, the marriage of high-content screening (HCS) with organoid models for drug discovery will be a critical component in this new era of drug development. This book chapter is focused on the state-of-the-art HCS technology and how this technology is being retooled for drug discovery and development with human organoids.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Reference Module in Chemistry, Molecular Sciences and Chemical Engineering
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
